factual

Pediatric vaccines authorized via immuno-bridging not outcomes

For younger ages the FDA used 'immuno-bridging'—requiring only that the vaccine produce antibody levels comparable to older ages—rather than proving reduction in symptomatic or severe disease, and large outcome trials were feasible (citing Salk's 400,000-person polio trial and Pfizer's $100B revenue) and could have enrolled a million eager parents.

factualpending

Speaker

Vinay Prasad

Evidence Quote

“Jonas Saul himself did a 400,000-person randomized trial of the polio vaccine many decades ago. I also want to remind people that Pfizer has been well-compensated... If you did a randomized trial and made it easy to enroll, you'll get 1 million people in one week.”

Source

Vinay Prasad on the Pandemic— EconTalk
Created: 6/13/2026, 12:17:03 AM

Your notes

Loading notes...